This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A protein comprising an immunoglobulin heavy chain (HC) variable domain ~~sequence~~ and an immunoglobulin light chain (LC) variable domain ~~sequence~~, wherein the HC variable domain ~~sequence~~ and the LC variable domain ~~sequence~~ form an antigen binding site that binds to an activated conformation of LFA-1, wherein the protein has one or more of the following properties:

(i) the heavy chain variable domain ~~sequence~~ comprises:

(a) a CDR1 that comprises ~~at least 3 amino acids from~~ RYVMW (SEQ ID NO: 1)

(b) a CDR2 that comprises ~~at least 13 amino acids from~~ YIWPSGGNTYYADSVKG (SEQ ID NO:2); and/or

(c) a CDR3 that comprises ~~at least 8 amino acids from~~ SYDFWSNAFDI (SEQ ID NO:3);

(ii) the light chain variable domain ~~sequence~~ comprises

(a) a CDR1 that comprises ~~at least 7 amino acids from~~ RASQSIGSYLN (SEQ ID NO:7);

(b) a CDR2 that comprises ~~at least 4 amino acids from~~ AASSLQS (SEQ ID NO:8); and/or

(c) a CDR3 that comprises ~~at least 5 amino acids from~~ QQSYSTPS (SEQ ID NO:9);

(iii) the heavy chain variable domain ~~sequence~~ comprises ~~a sequence at least 85% identical to the heavy chain variable domain sequence of the D2-57~~ SEQ ID NO:23, ~~DX-2001~~ SEQ ID NO:25, ~~C1-54~~ SEQ ID NO:27, or ~~P1-G10~~ SEQ ID NO:29 ~~antibody~~;

(iv) the light chain variable domain ~~sequence~~ comprises ~~a sequence at least 85% identical to the light chain variable domain sequence of the D2-57~~ SEQ ID NO:22, ~~DX-2001~~ SEQ ID NO:24, ~~C1-54~~ SEQ ID NO:26, or ~~P1-G10~~ SEQ ID NO:28 ~~antibody~~;

(v) the heavy chain variable domain ~~sequence~~ comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to a sequence that

encodes the heavy chain variable domain ~~sequence~~ of ~~the D2-57, DX-2001~~ SEQ ID NO:42, ~~C1-54~~ SEQ ID NO:43, or ~~P1-G10~~ SEQ ID NO:44 ~~antibody~~;

(vi) the light chain variable domain ~~sequence~~ comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to a sequence that encodes the light chain variable domain ~~sequence~~ of SEQ ID NO: 42 ~~the D2-57, DX-2001~~, ~~C1-54~~ SEQ ID NO:43, or ~~P1-G10~~ SEQ ID NO:44 ~~antibody~~; and/or

(vii) the protein which competes with an antibody ~~D2-57, DX-2001, C1-54, or P1-G10~~ selected from the group consisting of

a) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:23, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:22;

b) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:25, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:24;

c) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:27, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:26; and

d) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:29, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:28;

for binding to activated LFA-1.

Claim 2 (currently amended): The protein of claim 1 that comprises at least the CDR regions of (i) and (ii) ~~the D2-57 antibody~~.

Claim 3 (currently amended): The protein of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, at least SEQ ID NO:23 and SEQ ID NO:22 ~~are at least 90% identical to corresponding variable domain sequences of the D2-57 antibody~~.

Claim 4 (currently amended): The protein of claim 1 ~~any of claims 1~~ wherein at least the

protein framework ~~80% of the FR~~ regions are identical to ~~FR sequence from a human germline sequence or a FR sequence of D2-57~~ SEQ ID NO:33 (heavy chain) and SEQ ID NO:36 (light chain); ~~C1-54~~ SEQ ID NO:34 (heavy chain) and SE ID NO:37 (light chain); or P1-G10.

Claim 5 (currently amended): The protein of claim 1 wherein the heavy chain variable domain ~~domains sequence~~ comprises Xa-S-X2-D-X4-X5-S-X7-A-X8-X9-X10-X11 (SEQ ID NO:4), and

(i) Xa is S or N;

(ii) X2 is Y or F;

(iii) X4 is hydrophobic;

(iv) X5 is W or R;

(v) X7 is N or Y;

(vi) X9 is Y or F;

(vii) X10 is D, E or A; and

(viii) X11 is any amino acid.

Claim 6 (original): The protein of claim 1 that is not immunogenic in humans.

Claim 7 (original): The protein of claim 1 that is a full length IgG antibody.

Claim 8 (original): The protein of claim 1 that is an antigen binding fragment of an antibody, and does not include an Fc domain.

Claim 9 (original): The protein claim 1 that has at least a 20-fold preference for binding to activated LFA-1 relative to inactivated LFA-1.

Claim 10 (original): A protein comprising an immunoglobulin heavy chain (HC) variable domain sequence and an immunoglobulin light chain (LC) variable domain sequence, wherein

(i) the HC variable domain sequence and the LC variable domain sequence form

an antigen binding site that binds to an activated conformation of LFA-1 ("aLFA-1");

(ii) the protein inhibits ICAM-1 binding to LFA-1 on human peripheral blood mononuclear cells with an IC_{50} of less than 5 nM.

Claim 11 (currently amended): A pharmaceutical composition that ~~comprising~~ comprises the protein according to any of claims ~~claim~~ 1-10 and a pharmaceutically acceptable salt.

Claim 12 (withdrawn): A method of treating or preventing inflammation or an inflammatory disorder, the method comprising: administering the protein of claim 1 to a subject in an amount effective to treat or prevent the inflammation or the inflammatory disorder.

Claim 13 (withdrawn): The method of claim 12 wherein the protein is administered at dosages less than 1 mg/kg per week, for at least 2 weeks.

Claim 14 (withdrawn): The method of claim 12 wherein the subject has psoriasis or is predisposed to psoriasis.

Claim 15 (withdrawn): The method of claim 14 wherein the subject has stable, plaque psoriasis.

Claim 16 (withdrawn): The method of claim 12 wherein the subject has or is predisposed to a disorder that is caused at least in part by a T cell inflammatory response.

Claim 17 (withdrawn): The method of claim 12 wherein the subject has or is predisposed to rheumatoid arthritis.

Claim 18 (withdrawn): A method of suppressing an immune response, the method comprising: administering the protein of 1 to a subject in an amount effective to suppress an immune response of the subject.

Claim 19 (withdrawn): The method of claim 18 wherein the subject has or is about to receive a transplant.

Claim 20 (withdrawn): The method of claim 18 further comprising administering a second agent that modulates T-cell function.

Claim 21 (withdrawn): The method of claim 20 wherein the second agent that modulates T-cell function is an antibody to CD154 or an antibody to CD45RB.

Claim 22 (withdrawn): A method of treating or preventing a disorder in a subject, the method comprising:

identifying a subject in need of an anti-LFA-1 antibody that preferentially binds to the activated form of LFA-1, but which subject does not respond or tolerate an anti-LFA-1 antibody that binds to activated and non-activated LFA-1 protein with substantially the same affinity; and

administering the anti-LFA-1 antibody that preferentially binds to the activated form of LFA-1, to the subject.

Claim 23 (withdrawn): A method of modulating aLFA-1 activity, the method comprising:

providing an aLFA-1-binding protein of claim 1; and

contacting the protein to aLFA-1, in an amount sufficient to modulate aLFA-1 activity.

Claim 24 (withdrawn): The method of claim 23 wherein the contacting is *in vitro*.

Claim 25 (withdrawn): The method of claim 23 wherein the contacting is in vivo.

Claim 26 (withdrawn): The method of claim 23 wherein the protein is contacted to aLFA-1 in the vicinity of a neoplastic cell.

Claim 27 (withdrawn): The method of claim 23 wherein the protein is contacted to aLFA-1 in the vicinity of an endothelial cell.

Claim 28 (withdrawn): A method for detecting the presence of an aLFA-1 protein, in a sample, in vitro, the method comprising:

(i) contacting the sample with an aLFA-1-binding protein according to any of claims 1-10, under conditions that allow interaction of the aLFA-1-binding protein and the aLFA-1 protein to occur; and

(ii) detecting interaction between the aLFA-1-binding protein, and the sample.

Claim 29 (withdrawn): The method of claim 28 wherein at least one of the aLFA-1 binding protein or the aLFA-1 is immobilized.

Claim 30 (withdrawn): A method for detecting the presence of activated LFA-1 in vivo, the method comprising:

(i) administering to a subject an aLFA-1-binding protein, under conditions that allow interaction of the aLFA-1-binding protein and the aLFA-1 protein to occur; and

(ii) detecting location of the aLFA-1-binding protein in the subject or formation of a complex between the aLFA-1-binding protein and aLFA-1 in the subject.

Claim 31 (withdrawn): The method of claim 30 wherein the subject is a human subject.

Claim 32 (withdrawn): The method of claim 30 wherein the detecting comprises imaging the subject.

Claim 33 (withdrawn): The method of claim 30 wherein the aLFA-1-binding protein is labeled with an MRI detectable label.